Xintela AB (publ) (1XT.F)

0.0152 0.0000 (0.00%) At close: 03:08PM CEST

Xintela AB (publ)

Medicon Village
Lund 223 81
Sweden
46 4 62 75 65 00
https://www.xintela.se

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 21

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Gregory Batcheller B.Sc., J.D., L.L.M., LLM	Executive Chairman of the Board	383k	N/A	1957
Dr. Evy Lundgren-Åkerlund Assoc.Prof, BSc, Ph.D.	Chief Executive Officer	4.59M	N/A	1957
Mr. Gunnar Telhammar	CFO & Finance Director	N/A	N/A	1961
Ms. Lucienne Vonk	Chief Scientific Officer	N/A	N/A	N/A
Dr. Per Goran Oskar Norlen	Chief Medical Officer	N/A	N/A	1970
Camilla Wennersten	Director of Clinical Development	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Xintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. The company develops products based on XINMARK, a patented technology platform; XSTEM, a stem cell platform for the treatment of knee osteoarthritis and difficult-to-heal leg ulcers; EQSTEM for the joint disease treatment in horses; CANISTEM for stem cell treatment in dogs; and XACT, an analytical test for cartilage cells. It is also involved in the development of TARG9 and TARG10, therapeutic antibodies targeting integrin aiopi for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. The company's trademarks also include XINTELA and TARGINTA. Xintela AB (publ) was founded in 2009 and is based in Lund, Sweden.

Corporate governance

Xintela AB (publ)’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.